Kymera Therapeutics, INC Form 4 insider transactions

Baker Bros. Advisors LP and related entities report acquiring prefunded warrants and common stock in Kymera Therapeutics, increasing their beneficial ownership.

Jared Gollob, Chief Medical Officer of Kymera Therapeutics, exercised stock options and sold shares under a pre-arranged Rule 10b5-1 trading plan.

Director Booth Bruce of Kymera Therapeutics sold shares of common stock on July 9, 2024, through pre-arranged Rule 10b5-1 trading plans.

CEO Nello Mainolfi exercised stock options and disposed of shares of Kymera Therapeutics, Inc. on July 1, 2024.

BVF Partners and related entities report changes in their beneficial ownership of Kymera Therapeutics, including the acquisition of stock options and holdings of common stock and pre-funded warrants.

Bruce N. Jacobs, CFO of Kymera Therapeutics, reports exercising stock options and updating his beneficial ownership of company stock.

Director Pamela Esposito acquired stock options for 16,000 shares of Kymera Therapeutics, Inc.

Director Bruce Booth acquired stock options for 16,000 shares of Kymera Therapeutics common stock on June 18, 2024.

Director Jeffrey W. Albers acquired stock options for 16,000 shares of Kymera Therapeutics common stock on June 18, 2024.

Director Elena Ridloff acquired 16,000 stock options in Kymera Therapeutics, Inc. on June 18, 2024.

Director Gorjan Hrustanovic acquired 16,000 stock options in Kymera Therapeutics, vesting fully by June 18, 2025, or the next annual meeting.

Director John Maraganore acquired 16,000 stock options in Kymera Therapeutics, Inc. on June 18, 2024.

Leigh Morgan, a director at Kymera Therapeutics, acquired 16,000 stock options on June 18, 2024, exercisable for common stock.

Director Victor Sandor acquired 16,000 stock options in Kymera Therapeutics, Inc. on June 18, 2024.

CEO Nello Mainolfi exercised stock options and acquired shares through an employee stock purchase plan, increasing his beneficial ownership in Kymera Therapeutics.

Director Booth Bruce of Kymera Therapeutics sold shares of common stock on June 12 and 13, 2024, under pre-arranged Rule 10b5-1 trading plans.

Director Joanna Horobin exercised stock options and sold shares of Kymera Therapeutics, Inc. on June 7, 2024, according to a Form 4 filing.

Kymera Therapeutics' Chief Operating Officer, Jeremy G. Chadwick, sold 2,575 shares of common stock on May 23, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Baker Bros. Advisors LP reports the acquisition of stock options in Kymera Therapeutics on behalf of related entities and individuals, including Felix J. Baker, a director of Kymera.

Director Bruce Booth reports sales of Kymera Therapeutics (KYMR) common stock through pre-arranged 10b5-1 trading plans.

Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. sold shares of Kymera Therapeutics (KYMR) common stock between March 11 and March 13, 2024, under pre-arranged Rule 10b5-1 trading plans.

Director Bruce Booth, associated with Atlas Venture funds, executed multiple sales of Kymera Therapeutics (KYMR) common stock between March 11 and March 13, 2024, under pre-arranged Rule 10b5-1 trading plans.

Jared Gollob, Chief Medical Officer of Kymera Therapeutics, reports the acquisition of restricted stock units and stock options, as well as sales of common stock to cover tax obligations.

Chief Operating Officer of Kymera Therapeutics, Jeremy Chadwick, reports the acquisition of stock options and restricted stock units.

Ellen Chiniara, Chief Legal Officer of Kymera Therapeutics, reports the acquisition of restricted stock units and stock options.

Kymera Therapeutics CEO, Nello Mainolfi, was granted 530,000 stock options on March 1, 2024, which vest monthly over three years.

Bruce Jacobs, CFO of Kymera Therapeutics, reports acquisition of restricted stock units and stock options, as well as sales of common stock to cover tax obligations.

Chief Medical Officer Jared Gollob reports exercising stock options and selling shares of Kymera Therapeutics under a pre-arranged trading plan.